Articles On Kazia Therapeutics (ASX:KZA)

SYDNEY, Jan. 7, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking at the HC Wainwright BioConnect Con...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

SYDNEY, Dec. 14, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of Karen Krumeich as Chief Financial Officer. In this role,...

Karen Krumeich "brings to Kazia more than 30 years of experience in corporate finance, focused almost entirely on the life sciences sector, and has driven the growth of numerous private and public biotech companies”.

“There are no changes to earnings in the forecast period and we maintain our Buy (Speculative) recommendation.”

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

03 Dec 2021 - Kazia Therapeutics (ASX:KZA) has announced positive results from its Phase II study into the treatment of glioblastoma with paxalisib.

Kazia Therapeutics (KZA) opens the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug for brain tumours The 30-patient trial confirmed some previously-reported safety and effic...

The ASX 200 Health Index (XHJ) is down by 0.67% at the time of writing, compared to the broader index which is up by 0.47%. Alcidion Group (ASX:ALC) rose nearly 8% this morning, after revealing that it was a member of a consortium awarded a...

The study tested paxalisib's effectiveness in patients whose genetic profile confers resistance to the only other treatment available for this condition.

SYDNEY, Nov. 29, 2021 /PRNewswire/ – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblastoma (NCT03970447) has opened a...

The Sydney-based company’s flagship drug, paxalisib, is a candidate in a multi-drug platform study designed to identify promising new therapies for glioblastoma.  

He’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radiopharm Theranostics (ASX:RAD) to his boardroom rota after the nuclear medicine play listed on the ASX on Thursday – albeit limply. The count...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Highlights As per experts, the global cancer drug market is likely to accelerate in the upcoming years due to the widespread prevalence of cancer.  The increased focus of the healthcare sector on cancer research has been a critical fac...

SYDNEY, Nov. 16, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role,...

Dr Friend will be responsible for overseeing the development and commercialization of Kazia’s pipeline drug candidates, and collaborate with clinicians and scientists to advance the company’s research programs.

SYDNEY, Nov. 11, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse mi...

The ASX 200 Health Index (XHJ) is down by 1.0% at the time of writing, compared to the broader index which is down by 0.1%. Medical diagnostics company, Universal Biosensors (ASX:UBI), has entered into a collaboration agreement with Mayo Cl...

"There remains a desperate need for new treatment options in this disease, and we hope that paxalisib may be able to contribute to better outcomes for patients and their families,” says Kazia CEO.

Wall Street falls as US inflation hits 30-year high US stocks continued their slide overnight, as the latest data showed that consumer prices rose at a pace not seen since the early 1990s. Prices in the US jumped 0.9% in October, and 6.2% f...

ShareCafeDue Diligence Webinar – Kazia Therapeutics Presenter – James Garner CEO & Managing Director – Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company based in Sydney, Austral...

Kazia Therapeutics (KZA) enrols its first patient in the upcoming phase one clinical trial of EVT801 EVT801 is a small molecule inhibitor of VEGFR3 and works by hindering lymphangiogenesis, the formation of new lymphatic vessels around the...

The oncology-focused drug development company licensed the investigational cancer therapy, known as EVT801, from German biotech Evotec AG in April 2021.

The ASX 200 Health Index (XHJ) is up by 0.40% at the time of writing, compared to the broader index which is higher by 0.30%. Neurology specialist, Invex Therapeutics (ASX:IXC), soared 13% after announcing that it’s about to launch a Phase...

ASX-listed mobile health (mHealth) company Advanced Human Imaging (AHI) is moving forward with its planned dual-listing on the NASDAQ exchange Listing on the NASDAQ will place Advanced Human Imaging on one of the highest-quality and highes...

The Maxim Group has also put a 12-month target price of US$18 per ADS, saying the current stock price does not reflect its upside potential.

Edison has increased its valuation to A$375 million or A$2.83 per basic share from A$346 million or A$2.68 per basic share mainly due to rolling forward its Net Present Value (NPV).

SYDNEY, Oct. 6, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be he...

SYDNEY, Sept. 11, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annua...

ShareCafeHidden Gems Webinar Recap – CYP, AT1, NSB & KZA Catch up on the full webinar with presentations from Cynata Therapeutics (ASX: CYP), Atomo Diagnostics (ASX: AT1), NeuroScientific (ASX: NSB) & Kazia Therapeutics (ASX: KZA)...

ShareCafeA high quality pipeline of cancer drugs James Garner – Managing Director & CEO – Kazia Therapeutics Limited is an innovative oncology-focused biotechnology company. Kazia is working to develop therapies across a range of on...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

“The second calendar quarter has been a busy and productive period for Kazia, as we bed down three substantial cross-border licensing deals,” says CEO.

Kazia says its future success will be measured by commercialisation milestones after the company recorded its maiden revenue in the 2021 financial year.

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

All upfront payments from outbound partnering transactions in the first quarter have been received by Kazia.

SYDNEY, July 21, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on re...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

The fortunes of ASX healthcare shares can often swing on one momentous milestone. Examples of such a make-or-break event could be a breakthrough invention, successful product trial, or regulatory approval (or rejection). Such incidents can...

SYDNEY, June 30, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801...

The GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now open to the paxalisib arm in the US across several prestigious centres.

Summary Afterpay jumps on plans to expand reach with U.S. merchants Althea enters South African cannabis market worth US$667 million Bluechiip shares close strong on a settlement agreement with Labcon North America The S&P/ASX...

Summary The ASX 200 closed lower for the second day in a row, falling 0.32% to 7,275.30. The ASX health care and energy stocks were among top losers, while tech and consumer staples emerged as top gainers. Australian retailer Woolwort...